Structural failure in bridging stentgrafts for branched endovascular aneurysm repair: a case–control study

Sven R. Hauck¹, Alexander Kupferthaler¹,², Martin C. Freund³, Peter Pichler⁴, Marie-Elisabeth Stelzmüller⁵, Christopher Burghuber⁶, Marek Ehrlich⁵, Harald Teufelsbauer⁶, Christian Loewe¹ and Martin A. Funovics¹*

Abstract

Objective: To present a case series of spontaneous structural failure of bridging stentgrafts (BSGs) after branched endovascular aortic repair (bEVAR), as well as their failure types and their detection. While bEVAR is a safe and effective procedure, one main limitation is the reintervention rate associated with the BSGs. Structural failure of BSGs, defined as fabric disruption, stent fracture with leak or complete separation is a major cause for reinterventions and difficult to detect in computed tomography angiography (CTA).

Methods: From a multicenter bEVAR complication database, structural BSG failures were identified. Patient and BSG characteristics, detection mode, failure type, treatment and outcome were recorded and compared with bEVAR patients with intact BSGs.

Results: Twenty-three BSG failures were detected in 12 patients with only 43% directly identified in CTA, after a mean of 21.4 months after implantation. The BSGs were Advanta (n = 4), E-Ventus (n = 16) and BeGraft (n = 3) in 10 renal, 9 superior mesenteric, and 4 celiac branches. Relining with another BSG was successful in 20/22 cases, one BSG failure necessitated renal branch embolization (organ loss), and one mesenteric bypass surgery. Two reintervention-related mortalities occurred.

Conclusion: Structural failure of BSGs is a serious limitation for bEVAR, which can result in high reintervention rates and serious complications. BSG failure typically occurs in single-layer types and events are clustered in patients. The necessary reinterventions carry serious morbidity and mortality. Since the use as BSG in bEVAR is off-label with all current BSG manufacturers, caution is advised regarding patient-informed consent.

Keywords: Bridging stentgraft, Structural failure, Branched EVAR, Type 3 endoleak, bEVAR complication

Key points

- 23 cases of bridging stentgraft failures after branched EVAR were identified.
- In 57% the failures were not identified as such in the CT scans.
- 22% were incidental findings at angiography.
- Repair was associated with mortality and serious complications.
- Avoiding single-layer bridging stentgrafts and more frequent CT surveillance after one bridging stentgraft failure may improve outcome.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
**Introduction**

The introduction of fenestrated (fEVAR) and branched (bEVAR) endovascular aortic repair (EVAR) over the last two decades has expanded the applicability of endovascular aneurysm repair to practically all regions of the aorta [1–3]. With the refinement of the materials used and increasing expertise of operators, technical success rates, complication rates and long-term stability of aneurysm exclusion approach those of conventional EVAR [4–7].

However, bEVAR is not free from technological weaknesses [8, 9]: One of the reasons that lead to higher reintervention rates in bEVAR are the bridging stentgrafts (BSGs), which are used to connect the branches or fenestrations of the aortic main body with the ostia of the visceral arteries [10, 11]. BSGs are associated with a reintervention rate of up to 33% after 2–3 years and up to 50% after 5 years [12–14]. While there are several manufacturers producing stentgrafts of suitable sizes, none of them labelled the application as BSGs on the product instructions for use. Devices have entered clinical use before being specifically tested for their durability as BSGs and all products are currently used off-label for this special purpose [14, 15].

Between 2014 and 2019, we observed an unusually high number of BSG failures (BSG leaks, stent fractures, and complete graft disruption) necessitating complex reinterventions with mixed outcomes. The purpose of the present study was to characterize the detection, treatment and outcome of such structural failures in bEVAR BSGs, to assess potential causes and to compare their characteristics with interventions with intact BSGs through the follow-up.

**Materials and methods**

Patients with structural failures of BSGs after bEVAR between 2012 and 2020 detected during the follow-up after initially successful BSG deployment were identified in a multi-center bEVAR complication database, consisting of 3 centers. In a retrospective case–control study, the patient files, records of implanted products, outpatient protocols and all pertinent imaging data were retrieved from each respective patient. For inferential analysis, the bEVAR procedures with and without BSG failure from the largest contributing center, regarding bEVAR procedures in general, as well as failure occurrence, were compared. The study was approved by the institutional ethics committee.

**Implantation details**

All patients underwent preoperative computed tomography (CT) angiography (CTA) and application of anatomical suitability criteria: Up to 4 essential target vessels, celiac and superior mesenteric artery diameter 6–10 mm, renal artery diameter 4–8 mm, > 25 mm patent aortic lumen at target vessel level, branches located within 50 mm of target vessel ostium, sufficient iliofemoral access vessel diameter, adequate brachial vascular access.

All procedures were performed in general anesthesia with uni- or bilateral femoral access either percutaneously with suture-mediated closure devices (Proglide, Abbott Vascular, Chicago, IL) or surgical exposure of the common femoral artery.

Either off-the-shelf (T-branch, Cook medical, Bloomington, IL; E-nside, Jotec) or custom-made (CMD, Cook; e-Xtra, Jotec) branched stentgrafts were employed. Proximal thoracic and distal tubular or bifurcated extensions were used as indicated. Brachial access was used in most cases for BSG implantation, alternatively, a steerable sheath (Heli-FX, Medtronic, Minneapolis, IN) was used for complete femoral bEVAR. In cases of insufficient BSG length, an extension BSG was inserted, and in cases of severe anulation or kinking of the BSG, an inner bare nitinol (relining) stent was deployed at the operator’s discretion.

Type, length, and diameter of each BSG were retrieved from the intervention protocols. The maximal angle of the curve in each BSG was measured in the completion angiography images. Post-procedure, all patients received CTA at discharge, 6 months post-procedure, and yearly thereafter. The CTA was performed on multislice scanners with a collimation between 0.6 and 1 mm after i.v. contrast application in the arterial and venous phase. Multiplanar reformatations were available as needed. All CTA images were critically reviewed by an experienced interventional radiologist and screened for signs of BSG failure. Structural BSG failure was considered proven with either contrast extravasation exclusively adjacent to the BSG at CTA and/or if angiographic images with either a clear contrast jet exiting the BSG membrane (absent after repair with a second BSG) or direct wire passage through the BSG were documented angiographically. All CT scans of patients with manifest BSG failure were reassessed by 2 radiologists (S.H., M.F.) and classified according to the following outcome definitions:

**Outcome definitions**

BSG structural failure was defined as:

- Failure type 1: Fabric disruption with visible endoleak.
- Failure type 2: Fracture of the metallic stents in association with endoleak.
- Failure type 3: Complete structural separation of the stent in two parts.
BSG failure detection was classified into one of three modes:

Detection mode 1: Detection by CT scan with clear signs of BSG fracture.

Detection mode 2: After one or more CT scans classified as unspecific or type II endoleaks, BSG failure was confirmed at angiography.

Detection mode 3: After negative CT scan (at the respective branch) as incidental finding during angiography.

Fig. 1 Complete separation of right renal BSG with endoleak directly diagnosed at CTA (a), during angiography (b, c) and after successful relining (d).
(performed either during repair of a different BSG or main body extension).

**BSG types**

The choice of BSGs has evolved over the study period and was influenced by device availability, sheath size, cost, and observations of BSG failures.

The **Advanta V12** (Getinge, Goteborg, Sweden) is a balloon-expandable stainless steel stent encapsulated in a dual extruded polytetrafluoroethylene (ePTFE) layer.

The **BeGraft** and **BeGraft Plus Peripheral** (Bentley InnoMed, Hechingen, Germany) are comprised of an inner cobalt chromium stent covered by an ePTFE outer membrane. The membrane thickness was initially 0.1 mm and has been increased to 0.2 mm in 2015. In 01/2018, the BeGraft Peripheral Plus was introduced and incorporated two ePTFE-Stent systems inside each other, thus there are four layers from the outside: ePTFE—cobalt/chrome—ePTFE—cobalt/chrome.

The **E-ventus BX** (Cryolife/Jotec, Hechingen, Germany) consists of a cobalt chromium bare stent with an outer ePTFE membrane, similar to the BeGraft.

The **Viabahn VBX** stentgraft (W.L Gore & associates, Flagstaff, AZ) consists of a stainless steel balloon expandable stent structure, fully surrounded by ePTFE. The inner layer of the membrane is coated with Carmeda bioactive heparin surface with the goal of preventing stent thrombosis. The stent rings are not connected by metal but only by the polymer.

The **Viabahn** stentgraft (W.L Gore & associates, Flagstaff, AZ) is a self-expanding nitinol stent with a Propaten heparin-coated inner ePTFE membrane.

**Statistical analysis**

Continuous variables are given as mean ± standard deviation (SD). Categorical variables are given as absolute values and percent (%) for each group. Variables were tested using the Shapiro–Wilk-test for normal distribution. Levene’s test was used to check for equality of variances. Binary variables were analyzed with Fisher’s exact test. A two-sided independent samples t-test with 95% confidence intervals (CI) for normally distributed data, or the Mann–Whitney U-test were used for group comparison in regard of data distribution. Calculations were performed in SPSS 27.0 (IBM, Armonk, NY, USA). A \( p < 0.05 \) was considered significant.

**Results**

Out of 185 branches in 54 patients, we identified a total of 23 BSGs in 12 patients that were affected by structural failure after an initially successful implantation without defects occurring during the implantation (such as e.g., visible perforation during the application of stent in stent or in a religning procedure with a self-expandable stent). According to the grading system regarding the clinical significance of device failures by Chaikof et al., all of the device failures resulted either in the need of intervention (grade 2), or major complication or death (grade 3) [16]. Images of the respective failure modes before and after repair are shown in Figs. 1, 2 and 3. Detection of structural BSG failure occurred after a mean follow-up time of 21.44 ± 15.24 months after the index procedure. Detection mode 1 (clear signs of failure in CT) occurred in 10 BSGs (Figs. 1, 2, 3), detection mode 2 (undefined endoleak at CT confirmed at angiography) in 8 BSGs (Figs. 4, 5), and detection mode 3 (incidental at angiography after negative CT) in 5 BSGs (Figs. 6, 7). The failure types (see definition in Methods) were failure type 1 in 7 BSGs, failure type 2 in 12, and failure type 3 in 4. The
affected branches were celiac ($n=4$), SMA ($n=9$) and renal ($n=10$).

All but one BSG failures underwent angiography and an endovascular repair attempt after a mean time of $24.27 \pm 39.40$ days after detection (one procedure is still pending at the time of submission). In 20/22 BSGs (11 patients), successful endovascular deployment of a second BSG could be performed via a brachial approach with one ($n=7$) or two ($n=2$) Advanta V12 and one ($n=1$) or two ($n=2$) Begraft (Plus) and two ($n=7$) or 3 ($n=1$) Viabahn VBX. In one patient, a complete separation (failure type 3) of a right renal BSG could not be catheterized and the branch was intentionally plugged resulting in loss of the right kidney. In the same patient, another failure type 3 of the mesenteric BSG (again with impossible catheter passage) necessitated open surgery with iliomesenteric bypass. However, procedure-related complications included two mortalities, one from

![Fig. 3](image-url)
stentgraft-infection with multi-organ failure 13 months after endovascular BSG repair, the other from postoperative pneumonia after iliomesenteric bypass 4 days after BSG repair, as well as one loss of organ (kidney). The other patients had stable outcomes after BSG repair for the remainder of the follow-up of 41.7 ± 26.1 months.

For comparison purposes, the failed and intact BSG groups from the largest contributing center were assessed. Patients with BSG failure were younger and had more reinterventions prior to BSG failure (Reinterventions on other failed BSGs, or extensions of the main body due to endoleak). The main body for bEVAR was similar between groups with predominantly Jotec main bodies. However, failure occurred in 9/26 (35%) E-ventus and BeGraft BSGs, while 4/47 (8.5%) Advanta V12, and 0/19 Viabahn and BeGraft plus failures were detected. There was no difference in the percentage of branches religned with a bare nitinol stent (77 vs. 71%) and side branch extensions with an additional BSG (54 vs. 41%). Failed BSGs were shorter (55 vs 58 mm) and the flexion angle within the branch was larger (50° vs. 28°). Importantly, only four patients had one BSG failure, while 11 BSG failures occurred after one or more previous BSG failures in the same patient.

Tables 1 and 2 show patient and branch characteristics of the respective groups in detail. Table 3 shows detection and treatment details of the multicenter failed BSG group.

Discussion
We have observed the structural failure of 23 individual BSGs in 12 patients. All of these structural failures resulted in reinterventions indicated by high-pressure type 3 endoleaks or complete disruption of the stentgraft with disconnection of the arterial supply of the respective visceral organ. These complications not only put the
patients at risk of losing the respective organ, but also for aneurysm enlargement or rupture. The reinterventions themselves carried a substantial morbidity and mortality risk.

It is still unclear which factors predispose patients for subsequent BSG structural failure given the low publication incidence and case number. In this study, structural failure tends to occur clustered, as 8/12 patients had failures in more than one BSGs (6 patients in 2 BSGs, 1 in 3 BSGs, and 1 in all 4 BSGs). Contrary to previous suspicions, structural failure exists not only in single layered designs, but in various BSG types used at index procedure [10, 14]: Advanta V12, E-Ventus, and BeGraft. This could indicate that structural failure is, at least in part, contributable to patient-related factors rather than simply attributable to a single manufacturer. The demographics, comorbidities and aneurysm characteristics in the patients with structural failures were not different from other typical EVAR patient cohorts [1, 17]. Potentially certain arterial movements (respiratory or pulsatile) may play a role in premature material degradation, as they have been found to be associated with endoleak.

Fig. 5 Detection of an unspecified endoleak directly adjacent to the right renal BSG in arterial and venous CTA (a, b), confirmed to originate from a membrane disruption via angiography (c) and after successful relining (d)
formation in conventional EVAR [18]. However, dynamic pre- and postintervention CT studies are not routinely performed. The renal arteries have been reported to be subjected to greater angular movement and torsion than the celiac and mesenteric arteries [15, 19, 20]. However, stent fractures in renal arteries did not occur more frequently in our data set (in 10/23 BSGs) [21]. Potentially, mechanical characteristics of the branch main stentgraft could also contribute to early BSG failure. While BSG failures are slightly overrepresented in the branched Jotec stentgrafts, which were predominantly used in our cohort, larger multicentric data sets are necessary before implications in this direction can be made.

Another factor that may put BSGs at risk for structural failure are prior reinterventions. We observed de-novo BSG failure as early as two weeks after a reintervention. In addition, significantly more prior reinterventions had been performed in BSG failures (either on another BSG or on the main body), compared to intact BSGs (65% vs. 42%, $p < 0.001$). Potentially, the BSGs in some patients are subjected to higher than average stress resulting in the observed clustered failures; however, possible causes for this stress remain as yet unknown.

In addition to the clustered occurrence of BSG failures, we also observed difficulties in their detection and differential diagnosis in routine follow-up CT scans. Only 10 of 23 BSG failures were clearly identified as such at CT, the remainder typically showed signs of endoleak not attributable to a specific source during multiple subsequent CT scans, leading to increased number of investigations and a delay in diagnosis. In 5 of 23 BSGs, CT did not show any endoleak and the failure was detected incidentally during angiography. Given the fact that in the last stage of BSG failure, the complete separation of the components, endovascular repair may prove impossible and subjects the patient to considerable morbidity and mortality, BSG failure detection at an earlier stage seems desirable. It seems advisable to implement shorter surveillance intervals in patients after one BSG failure. Further, bEVAR patients could profit from CT follow-up scans with higher spatial resolution around the aorta at the cost of a reduced field of view as used in cardiac CT protocols [22]. Finally, a more liberal indication to angiography when unspecific endoleaks are reported at CT scans may aid in detecting BSG failures at an earlier stage. On the side of the interpreting radiologist, a clear understanding of the function and weaknesses of BSGs and a tailored CT angiography protocol, potentially with higher resolution and/or time-resolved post contrast series, may aid in earlier detection and less invasive repair [23, 24]. Since 19 of the 23 BSG failures occurred in single-layered stentgrafts, it seems unwise to continue their use in bEVAR, as several double-layer stentgrafts are now readily available, although with larger sheath sizes and higher cost.

Currently there are no stentgraft manufacturers who include the use of their products as BSGs for bEVAR in their instructions for use. Consequently, all types of BSGs for bEVAR are used off-label [14, 15]. Since structural failures were observed with single- and double-layered BSG types, a dedicated BSG would probably need more structural strength and material durability than the currently available products [21, 25]. Further development of stentgrafts is ongoing and yields promising results toward more resilience [26, 27].

In the foreseeable future, bEVAR will be expanded in its indications and in its frequency to an ever-larger patient cohort as a powerful alternative to thoracoabdominal open aortic replacement [28]. Currently there is no candidate for a dedicated BSG announced so we will
be faced with an ever-increasing number of off-label use in the necessary BSGs. Alternatively, an existing product with marginal improvements might prematurely be labelled as suitable for this task, but the results of this and similar studies advise caution. Compared with current rates in literature, structural failures are probably underreported [16, 29] and the more widespread use of bEVAR will undoubtedly bring up more BSG failures. While some users have learned to put the blame on the material last, this may not necessarily hold true in this application. Especially BSGs require clinical validation and monitoring as a relatively newly developed technology rather than just relying on bench tests [16].

Stricter quality controls may be in order given the fact that the detected structural failures in BSGs occurred at a mean time of 21 months after insertion. Also, the practice of relining BSGs with self-expanding nitinol stents must be reassessed, as the spikes of the inner stent potentially contribute to early material fatigue. Our data did however not show a trend to more failures in religned BSGs. On the other hand, a greater curve of the BSG was associated with higher failure rates. Thus, an even more
Table 1  Baseline demographic and clinical characteristics of study population

|                                | BSG failure from database (n = 12 patients) | BSG failure cohort single center (n = 6 patients) | Control cohort single center (n = 25 patients) | p (CI of difference)* |
|--------------------------------|---------------------------------------------|-------------------------------------------------|-----------------------------------------------|-----------------------|
| Mean age, y                    | 67.25 (± 9.22)                              | 61.73 (± 8.39)                                  | 71.84 (± 9.4)                                  | 0.022 (1.5; 18.7)     |
| Male sex                       | 10 (83.3%)                                  | 5 (83.3%)                                       | 15 (60%)                                      | 0.383                 |
| Comorbidities                  |                                             |                                                 |                                               |                       |
| Hypertension                   | 11 (91.7%)                                  | 5 (83.3%)                                       | 24 (96%)                                      | 0.355                 |
| Hyperlipidemia                 | 10 (83.3%)                                  | 6 (100%)                                        | 20 (80%)                                      | 0.553                 |
| Diabetes mellitus II           | 3 (25%)                                     | 2 (33.3%)                                       | 7 (28%)                                       | 1.000                 |
| Smoking                        | 4 (33.3%)                                   | 2 (33.3%)                                       | 9 (36%)                                       | 1.000                 |
| COPD                           | 4 (33.3%)                                   | 2 (33.3%)                                       | 8 (32%)                                       | 1.000                 |
| CKD                            | 5 (41.7%)                                   | 3 (50%)                                         | 7 (28%)                                       | 0.358                 |
| Atrial fibrillation            | 0 (0%)                                      | 0 (0%)                                          | 5 (20%)                                       | 0.553                 |
| Heart failure                  | 1 (8.3%)                                    | 0 (0%)                                          | 2 (8%)                                        | 1.000                 |
| Cancer                         | 1 (8.3%)                                    | 1 (16.7%)                                       | 5 (20%)                                       | 1.000                 |
| Arterial disease               |                                             |                                                 |                                               |                       |
| Coronary                       | 5 (41.7%)                                   | 3 (50%)                                         | 10 (40%)                                      | 0.676                 |
| Peripheral                     | 1 (8.3%)                                    | 0 (0%)                                          | 6 (24%)                                       | 0.309                 |
| Central                        | 0 (0%)                                      | 0 (0%)                                          | 6 (24%)                                       | 0.309                 |
| Aortic surgery/intervention priorly | 5 (41.7%)                               | 3 (50%)                                         | 10 (40%)                                      | 1.000                 |
| Indication                     |                                             |                                                 |                                               | 0.391                 |
| TAAA, Crawford:                |                                             |                                                 |                                               |                       |
| I                              | 1 (8.3%)                                    | 1 (16.7%)                                       | 2 (8%)                                        |                       |
| II                             | 4 (33.3%)                                   | 2 (33.3%)                                       | 6 (24%)                                       |                       |
| III                            | 0 (0%)                                      | 0 (0%)                                          | 0 (0%)                                        |                       |
| IV                             | 5 (41.7%)                                   | 3 (50%)                                         | 15 (60%)                                      |                       |
| V                              | 2 (16.7%)                                   | 0 (0%)                                          | 2 (8%)                                        |                       |
| Mean aneurysm Ø, mm            | 71.00 (± 0.79)                              | 72.33 (± 4.15)                                  | 66.12 (± 2.3)                                 | 0.247                 |
| Urgency                        |                                             |                                                 |                                               | 0.654                 |
| Acute                          | 0 (0%)                                      | 0 (0%)                                          | 1 (4%)                                        |                       |
| Urgent                         | 2 (16.7%)                                   | 2 (33.3%)                                       | 4 (16%)                                       |                       |
| Elective                       | 10 (83.3%)                                  | 4 (66.7%)                                       | 20 (80%)                                      |                       |
| Index procedure                 |                                             |                                                 |                                               | 1.000                 |
| Main body                      |                                             |                                                 |                                               |                       |
| Jotec                          | 11 (91.7%)                                  | 5 (83.3%)                                       | 20 (80%)                                      |                       |
| Cook                           | 1 (8.3%)                                    | 1 (16.7%)                                       | 5 (20%)                                       |                       |
| Total br, n                    | 44                                           | 23                                              | 85                                            |                       |
| Mean br/pt                     | 3.67 (± 0.65)                               | 3.83 (± 0.41)                                   | 3.4 (± 0.96)                                  | 0.391                 |
| Successful br, n               | 44                                           | 23                                              | 84                                            |                       |
| Successful br/pt               | 3.67 (± 0.65)                               | 3.83 (± 0.41)                                   | 3.36 (± 0.95)                                 | 0.314                 |
| Religning, n                   | 17                                           | 17                                              | 58                                            |                       |
| Religning/pt                   | 1.42 (± 1.78)                               | 2.83 (± 1.47)                                   | 2.32 (± 1.52)                                 | 0.542                 |
| Extensions, n                  | 18                                           | 11                                              | 35                                            |                       |
| Extension/pt                   | 1.50 (± 1.17)                               | 1.83 (± 1.17)                                   | 1.40 (± 1.63)                                 | 0.339                 |
| TAM, n                         | 35                                           | 28                                              | 93                                            |                       |
| TAM/pt                         | 2.92 (± 2.47)                               | 4.67 (± 2.16)                                   | 3.72 (± 2.30)                                 | 0.368 (− 3.1; 1.2)    |
| Technical success of BSG       |                                             |                                                 |                                               | 0.330                 |
| Primary                        | 10 (83.3%)                                  | 4 (66.7%)                                       | 22 (88%)                                      |                       |
| Assisted                       | 2 (16.7%)                                   | 2 (33.3%)                                       | 2 (8%)                                        |                       |
| Reintervention 30 days         | 3 (25%)                                     | 2 (33.3%)                                       | 7 (28%)                                       | 1.000                 |
| Aortic reintervention (prior to BSG failure) | 7 (58.3%)                               | 6 (100%)                                       | 9 (36%)                                       | 0.007                 |
| FU CT/Angiography, months      | 41.69 (± 26.06)                             | 58.43 (± 26.54)                                 | 19.89 (± 34.43)                               | 0.009                 |
| FU clinically, months          | 41.71 (± 26.07)                             | 58.47 (± 26.53)                                 | 21.80 (± 34.30)                               | 0.012                 |
| BSG related mortality          | 2 (16.7%)                                   | 2 (33.3%)                                       | 0 (0%)                                        | 0.032                 |
watchful eye in postoperative CT surveillance should be
turned toward BSGs with significant angulation.

Since the products are used off-label and a relevant chance of failure of the product in this position exists, there are likely consequences regarding legal responsibility and patient-informed consent. Uncertainties in this respect may contribute to a negative publication bias: To report complications of an off-label use with unclear accountabilities may deter some researchers. As bEVAR will continue to be a valuable and necessary treatment option, clear guidelines concerning the necessary off-label use of BSGs are needed. So far manufacturers leave physicians in the cold regarding this aspect.

Limitations of the study include the relatively low event count, even in a multicenter approach. The increased frequency of bEVAR in our center over the last 2 years contributes to the shorter mean follow-up in the control group. Moreover, changes in the used BSG types may distort apparent failure rates across the different manufacturers. Larger registries will be needed to draw inferential conclusions as to which factors contribute to BSG failure and to investigate the clustered occurrence. Hopefully, this publication will create awareness and encourage more uniform reporting standards, thereby facilitating the creation of said registries.

**Conclusion**

Structural failures of BSGs after bEVAR with potentially serious consequences occur throughout the available product range. Moreover, they arise in a product that has been intentionally used off-label because there are no dedicated products for this purpose available. Our data
show that previous structural failure in one BSG, aortic reinterventions and BSG angulation and the use of single-layer BSGs are risk factors for BSG failure in the same patient. As of yet there are no clear additional indicators which procedures or patients are more prone to structural failure than others. It seems advisable to keep an open eye on early stages of structural failure during the follow-up CT scans after bEVAR and be aware about patient-informed consent regarding BSGs.

**Abbreviations**

bEVAR: Branched endovascular aortic repair; BSG: Bridging stentgraft; CI: Confidence interval; CT: Computed tomography; CTA: Computed tomography angiography; ePTFE: Extruded polytetrafluorethylene; EVAR: Endovascular aortic repair; TEVAR: Fenestrated endovascular aortic repair; SD: Standard deviation.

**Authors’ contributions**

SRH has made substantial contributions to the design of the work, the acquisition, analysis and interpretation of data and was a major contributor in writing and revising the manuscript. AK has made substantial contributions to the design of the work, acquisition of data and writing the manuscript. MCF has made substantial contributions to the design of the work and the acquisition of data. PP has made substantial contributions to the design of the work and the acquisition of data. ME has made substantial contributions to the design of the work, acquisition of data and substantively revised the manuscript. All authors read and approved the final manuscript.

**Funding**

No funding was received for this study.

### Table 3 Detection and treatment details of all failed BSG

| Detection mode                  | Number (Percentage) |
|--------------------------------|---------------------|
| 1 (Type III EL in CT)          | 10 (43.5%)          |
| 2 (Unspecific EL in CT)        | 8 (34.8%)           |
| 3 (Incidental finding at Angiography) | 5 (21.7%)        |
| Time to detection, months      | 21.44 (± 15.24)     |
| Previous BSG failure           | 10 (43.5%)          |

| Failure type                    | Number (Percentage) |
|--------------------------------|---------------------|
| 1 (Membrane disruption)         | 7 (30.4%)           |
| 2 (Membrane and wire fracture)  | 12 (52.2%)          |
| 3 (Complete separation)        | 4 (17.4%)           |

| Treatment, 22 treated, 1 treatment pending | Relining | Plug | Bypass | Time to treatment, days | Endovascular technical success | Complication of intervention |
|-------------------------------------------|---------|------|--------|-------------------------|-------------------------------|-----------------------------|
|                                           | 20 (90.9%) | 1 (4.5%) | 1 (4.5%) | 24.27 (± 39.40) | 20/22 (90.91%) | 2 (14.3%) |

**BSG** bridging stentgraft, CT computed tomography, EL endoleak

### Availability of data and material

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

### Declarations

#### Ethics approval and consent to participate

The study was approved by the ethics committee of the Medical University of Vienna. Patient-informed consent was waived due to the retrospective nature of the study.

#### Consent for publication

Not applicable.

#### Competing interests

Christian Loeve is a member of the Insights into Imaging Editorial Board. He has not taken part in the review or selection process of this article. All remaining authors declare that they have no competing interests.

### References

1. Oderich GS, Ribeiro M, Hofer J et al (2017) Prospective, nonrandomized study to evaluate endovascular repair of pararenal and thoracoabdominal aortic aneurysms using fenestrated-branched endografts based on supraceliac sealing zones. J Vasc Surg 65:1249–1259.e10
2. Armstrong N, Burgers L, Deshpande S et al (2014) The use of fenestrated and branched endovascular aneurysm repair for juxtarenal and thoracoabdominal aortic aneurysms: a systematic review and cost-effectiveness analysis. Health Technol Assess 18:1–66
3. Rybicki B, Czerny M, Sudkamp M, Russe M, Siepe M, Beyersdorf F (2015) Fenestrated and branched aortic grafts. Dtsch Arztebl Int 112:816–822
4. Walker J, Kaushik S, Hoffman M et al (2019) Long-term durability of multibranchendovascular repair of thoracoabdominal and pararenal aortic aneurysms. J Vasc Surg 69:341–347
5. Mastracci TM, Eagleton MJ, Kuramochi Y, Bathurst S, Wolski K (2015) Twelve-year results of fenestrated endografts for juxtarenal and group IV thoracoabdominal aneurysms. J Vasc Surg 61:355–364
6. Panuccio G, Bisdas T, Berekoven B, Torsello G, Austermann M (2015) Performance of bridging stent grafts in fenestrated and branched aortic endografting. Eur J Vasc Endovasc Surg 50:60–70
7. Osman E, Tan KT, Tse L et al (2015) The in-hospital costs of treating high-risk patients with fenestrated and branched endografts. J Vasc Surg 62:1457–1464
8. Marzelle J, Presles E, Becquemin JP (2015) Results and factors affecting early outcome of fenestrated and/or branched stent grafts for aortic aneurysms: a multicenter prospective study. Ann Surg 261:197–206
9. Rambau V, Blanco Amil C, Capoccia L, Mestres G, Yugueros X (2020) FEVAR/BEVAR have limitations and do not always represent the preferred option for juxtarenal reconstruction. J Cardiovasc Surg (Torino) 61:10–17
10. Lindstrom D, Kettunen H, Engstrom J, Lundberg G (2020) Outcome after fenestrated and branched repair of anortic aneurysms-device failures predict reintervention rates. Ann Vasc Surg 66:142–151
11. Fillinger MF, Greenberg RK, McKinsey JE, Chaikof EL (2010) Reporting standards for thoracic endovascular aortic repair (TEVAR). J Vasc Surg 52:1022–1033
12. Oderich GS, Ribeiro M, Reis de Souza L, Hofer J, Wigham J, Cha S (2017) Endovascular repair of thoracoabdominal aortic aneurysms using fenestrated and branched endografts. J Thorac Cardiovasc Surg 153:532–541
13. Dossabhoy SS, Simons JP, Diamond KR et al (2018) Reinterventions after fenestrated or branched endovascular aortic aneurysm repair. J Vasc Surg 68:669–681
14. Lindstrom D, Mani K, Lundberg G, Wanhainen A (2019) Bridging stent grafts in fenestrated and branched endovascular aortic repair: current practice and possible complications. J Cardiovasc Surg (Torino) 60:476–484
15. Gibello L, Ruffino MA, Varetto G, Frola E, Rispoli P, Verzini F (2020) Current results of balloon expandable visceral stent-grafts in fenestrated endografting. J Cardiovasc Surg (Torino) 61:37–46
16. Chaikof EL, Blankensteijn JD, Harris PL et al (2002) Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 35:1048–1060
17. Sweeting MJ, Patel R, Powell JT, Greenhalgh RM (2017) Endovascular repair of abdominal aortic aneurysm in patients physically ineligible for open repair: very long-term follow-up in the EVAR-2 randomized controlled trial. Ann Surg 266:713–719
18. Asenbaum U, Schoder M, Schwartz E et al (2019) Stent-graft surface movement after endovascular aneurysm repair: baseline parameters for prediction, and association with migration and stent-graft-related endoleaks. Eur Radiol 29:6385–6395
19. Ullery BW, Suh GY, Lee JT et al (2015) Geometry and respiratory-induced deformation of abdominal branch vessels and stents after complex endovascular aneurysm repair. J Vasc Surg 61:875–884
20. Gallitto E, Faggioli G, Pini R et al (2018) Renal artery orientation influences the renal outcome in endovascular thoraco-abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 56:382–390
21. Mastracci TM, Carrell T, Constantinoj J et al (2016) Editor’s choice: effect of branch stent choice on branch-related outcomes in complex aortic repair. Eur J Vasc Endovasc Surg 51:536–542
22. Meijer FJA, Schuijf JD, de Vries J, Boogaarts HD, van der Woude WJ, Prokop M (2019) Ultra-high-resolution subtraction CT angiography in the follow-up of treated intracranial aneurysms. Insights Imaging 10:2
23. Berczeli M, Lumsden AB, Chang SM, Bavare CS, Chinnadurai P (2021) Dynamic, time-resolved computed tomography angiography technique to characterize aortic endoleak type, inflow and provide guidance for targeted treatment. J Endovasc Ther. https://doi.org/10.1177/15266028211037986
24. Vrtiska TJ, Macedo TA, Oderich GS (2017) Computed tomography/computed tomography angiography for evaluation, planning, and surveillance of complex endovascular repair. In: Oderich GS (ed) Endovascular aortic repair. Springer, Cham, pp 149–188
25. Bertoglio L, Loschi D, Cambiaghi T et al (2018) Preliminary outcomes of the LifeStream balloon-expandable covered stent in fenestrated and branched thoracoabdominal endovascular repairs. J Endovasc Ther 25:230–236
26. Georgarakos E, Koutsoumpelis A (2019) Commentary: use of BeGraft and BeGraft+ stent-grafts in the management of complex aortic aneurysms: toward more dedicated stent-graft platforms? J Endovasc Ther 26:795–796
27. Torsello GF, Herten M, Frank A et al (2019) Performance of BeGraft and BeGraft+ stent-grafts as bridging devices for fenestrated endovascular aneurysm repair: an in vitro study. J Endovasc Ther 26:787–794
28. Scharner A, Simons JP, Flihove J et al (2017) Outcomes of fenestrated and branched endovascular repair of complex abdominal and thoracoabdominal aortic aneurysms. J Vasc Surg 66:687–694
29. Mezzetto L, Scorsone L, Silingardi R et al (2021) Bridging stents in fenestrated and branched endovascular aneurysm repair: a systematic review. Ann Vasc Surg 73:454–462

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:
► Convenient online submission
► Rigorous peer review
► Open access: articles freely available online
► High visibility within the field
► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com